Growth Metrics

Merck (MRK) Gains from Investment Securities (2016 - 2026)

Merck has reported Gains from Investment Securities over the past 18 years, most recently at $66.0 million for Q1 2026.

  • Quarterly Gains from Investment Securities rose 160.55% to $66.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $233.0 million through Mar 2026, up 5725.0% year-over-year, with the annual reading at $58.0 million for FY2025, 54.33% down from the prior year.
  • Gains from Investment Securities was $66.0 million for Q1 2026 at Merck, down from $172.0 million in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $330.0 million in Q3 2025 and troughed at -$975.0 million in Q3 2022.
  • The 5-year median for Gains from Investment Securities is $14.0 million (2024), against an average of -$59.6 million.
  • The largest YoY upside for Gains from Investment Securities was 243.07% in 2024 against a maximum downside of 1265.0% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at -$132.0 million in 2022, then skyrocketed by 115.91% to $21.0 million in 2023, then skyrocketed by 171.43% to $57.0 million in 2024, then soared by 201.75% to $172.0 million in 2025, then crashed by 61.63% to $66.0 million in 2026.
  • Per Business Quant, the three most recent readings for MRK's Gains from Investment Securities are $66.0 million (Q1 2026), $172.0 million (Q4 2025), and $330.0 million (Q3 2025).